Suresh K. Durgam - Feb 18, 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chief Medical Officer
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Feb 18, 2022
Transactions value $
-$230,958
Form type
4
Date filed
2/23/2022, 06:08 PM
Previous filing
Jan 20, 2022
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +8.35K +36.16% 31.5K Feb 18, 2022 Direct F1
transaction ITCI Common Stock Sale -$157K -2.82K -8.96% $55.53 28.6K Feb 22, 2022 Direct F2, F3
transaction ITCI Common Stock Sale -$74.4K -1.36K -4.74% $54.80 27.3K Feb 22, 2022 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -8.35K -50% $0.00 8.35K Feb 18, 2022 Common Stock 8.35K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.15 to $56.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.55 to $55.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 Each restricted stock unit represents a contingent right to receive one share of common stock.
F6 On February 18, 2020, the reporting person was granted 25,062 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.